Design Therapeutics (DSGN) Preferred Stock Liabilities (2020)

Design Therapeutics has disclosed Preferred Stock Liabilities across 1 years of filings, most recently posting $45.4 million for Q4 2020.

• Preferred Stock Liabilities for Q4 2020 came in at $45.4 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2020 was $45.4 million (changed N/A YoY), and the FY2020 annual result was $45.4 million, changed N/A from the prior year.
• Preferred Stock Liabilities came in at $45.4 million for Q4 2020 at Design Therapeutics, roughly flat from $45.4 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $45.4 million in Q1 2020 to a low of $45.4 million in Q1 2020.